Morgan Stanley Karuna Therapeutics, Inc. Transaction History

Morgan Stanley

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$161.01 - $317.85 $16.8 Million - $33.2 Million	104,356 Added 201.91%	156,041 $49.4 Million
Q3 2023 Nov 15, 2023	SELL	$164.66 - $218.08 $8.63 Million - $11.4 Million	-52,432 Reduced 50.36%	51,685 $8.74 Million
Q2 2023 Aug 14, 2023	BUY	$176.32 - $240.22 $1.92 Million - $2.61 Million	10,884 Added 11.67%	104,117 $22.6 Million
Q1 2023 May 15, 2023	SELL	$161.33 - $204.36 $3.06 Million - $3.88 Million	-18,970 Reduced 16.91%	93,233 $16.9 Million
Q4 2022 Feb 14, 2023	SELL	$191.53 - $236.82 $6.5 Million - $8.04 Million	-33,941 Reduced 23.22%	112,203 $22 Million

Q3 2022 Nov 14, 2022	SELL	$123.79 - $277.42 $840,286 - $1.88 Million	-6,788 Reduced 4.44%	146,144 $32.9 Million
Q2 2022 Oct 27, 2022	BUY	$93.97 - $143.33 $2.05 Million - $3.13 Million	21,847 Added 16.67%	152,932 $19.3 Million
Q2 2022 Aug 15, 2022	BUY	$93.97 - $143.33 $2.05 Million - $3.13 Million	21,847 Added 16.67%	152,932 $19.3 Million
Q1 2022 Oct 27, 2022	SELL	$98.9 - $132.37 $2.16 Million - $2.89 Million	-21,847 Reduced 14.29%	131,085 $16.6 Million
Q1 2022 May 13, 2022	BUY	$98.9 - $132.37 $5.15 Million - $6.9 Million	52,114 Added 65.99%	131,085 $16.6 Million
Q4 2021 Feb 14, 2022	BUY	$110.64 - $159.4 $3.26 Million - $4.7 Million	29,480 Added 59.57%	78,971 $10.3 Million
Q3 2021 Nov 15, 2021	BUY	$101.2 - $125.87 $5.01 Million - $6.23 Million	49,491 New	49,491 $6.05 Million

333K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.